Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study.


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
06 10 2021
Historique:
received: 29 06 2021
accepted: 29 09 2021
entrez: 7 10 2021
pubmed: 8 10 2021
medline: 1 2 2022
Statut: epublish

Résumé

Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistance measured by estimated glucose disposal rate (eGDR) and risk of stroke and mortality thereof in people with T2D. Nationwide population based observational cohort study that included all T2D patients from the Swedish national diabetes registry between 2004 and 2016 with full data on eGDR and categorised as following: < 4, 4-6, 6-8, and ≥ 8 mg/kg/min. We calculated crude incidence rates and 95% confidence intervals (CIs) and used multiple Cox regression to estimate hazard ratios (HRs) to assess the association between the risk of stroke and death, according to the eGDR categories in which the lowest category < 4 (i.e., highest grade of insulin resistance), served as a reference. The relative importance attributed of each factor in the eGDR formula was measured by the R A total of 104 697 T2D individuals, 44.5% women, mean age of 63 years, were included. During a median follow up-time of 5.6 years, 4201 strokes occurred (4.0%). After multivariate adjustment the HRs (95% CI) for stroke in patients with eGDR categories between 4-6, 6-8 and > 8 were: 0.77 (0.69-0.87), 0.68 (0.58-0.80) and 0.60 (0.48-0.76), compared to the reference < 4. Corresponding numbers for the risk of death were: 0.82 (0.70-0.94), 0.75 (0.64-0.88) and 0.68 (0.53-0.89). The attributed relative risk R A low eGDR (a measure of insulin resistance) is associated with an increased risk of stroke and death in individuals with T2D. The relative attributed risk was most important for hypertension.

Sections du résumé

BACKGROUND AND AIMS
Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistance measured by estimated glucose disposal rate (eGDR) and risk of stroke and mortality thereof in people with T2D.
MATERIALS AND METHODS
Nationwide population based observational cohort study that included all T2D patients from the Swedish national diabetes registry between 2004 and 2016 with full data on eGDR and categorised as following: < 4, 4-6, 6-8, and ≥ 8 mg/kg/min. We calculated crude incidence rates and 95% confidence intervals (CIs) and used multiple Cox regression to estimate hazard ratios (HRs) to assess the association between the risk of stroke and death, according to the eGDR categories in which the lowest category < 4 (i.e., highest grade of insulin resistance), served as a reference. The relative importance attributed of each factor in the eGDR formula was measured by the R
RESULTS
A total of 104 697 T2D individuals, 44.5% women, mean age of 63 years, were included. During a median follow up-time of 5.6 years, 4201 strokes occurred (4.0%). After multivariate adjustment the HRs (95% CI) for stroke in patients with eGDR categories between 4-6, 6-8 and > 8 were: 0.77 (0.69-0.87), 0.68 (0.58-0.80) and 0.60 (0.48-0.76), compared to the reference < 4. Corresponding numbers for the risk of death were: 0.82 (0.70-0.94), 0.75 (0.64-0.88) and 0.68 (0.53-0.89). The attributed relative risk R
CONCLUSION
A low eGDR (a measure of insulin resistance) is associated with an increased risk of stroke and death in individuals with T2D. The relative attributed risk was most important for hypertension.

Identifiants

pubmed: 34615525
doi: 10.1186/s12933-021-01394-4
pii: 10.1186/s12933-021-01394-4
pmc: PMC8495918
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0
Glycated Hemoglobin A 0
hemoglobin A1c protein, human 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

202

Subventions

Organisme : hjärt-lungfonden
ID : 20190298
Organisme : alf stockholms läns landsting and karolinska institutet (grant 20170120).
ID : 20170120

Informations de copyright

© 2021. The Author(s).

Références

Diabetes Care. 2019 Jul;42(7):1297-1304
pubmed: 31048408
PLoS One. 2017 Mar 14;12(3):e0171334
pubmed: 28291782
Diabetes Care. 2008 Oct;31(10):2038-43
pubmed: 18591403
J Am Coll Cardiol. 2012 Jan 3;59(1):74-83
pubmed: 22192672
Lancet. 2010 Jul 10;376(9735):112-23
pubmed: 20561675
Lancet. 2010 Feb 6;375(9713):481-9
pubmed: 20110121
Diabetes Obes Metab. 2018 Mar;20(3):556-563
pubmed: 28884949
Diabetes Care. 2009 Feb;32(2):361-6
pubmed: 19017770
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
pubmed: 19896746
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Diabetes Care. 2003 Feb;26(2):360-6
pubmed: 12547863
Diabetes. 2000 Apr;49(4):626-32
pubmed: 10871201
Cerebrovasc Dis. 2014;37(6):393-400
pubmed: 24993381
Diabetes Care. 2013 Aug;36(8):2280-5
pubmed: 23596179
Stroke. 2005 Dec;36(12):2538-43
pubmed: 16282538
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Diabetes Res Clin Pract. 2014 Dec;106 Suppl 2:S291-4
pubmed: 25550056
Int J Cardiol. 2016 Apr 1;208:141-6
pubmed: 26855067
J Hypertens. 2012 Oct;30(10):2020-30
pubmed: 22871895
N Engl J Med. 2012 Jul 26;367(4):319-28
pubmed: 22686416
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Heart Vessels. 2017 Mar;32(3):269-278
pubmed: 27401741
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Diabetologia. 2009 Jan;52(1):65-73
pubmed: 18985314
Med Clin North Am. 2018 Jan;102(1):13-33
pubmed: 29156181
Diabetes Obes Metab. 2020 Feb;22(2):182-190
pubmed: 31576643
Clin Chem. 2004 Jan;50(1):166-74
pubmed: 14709644
Neurology. 2002 Sep 24;59(6):809-15
pubmed: 12349850
Biostatistics. 2012 Apr;13(2):315-25
pubmed: 22190711
Eur J Prev Cardiol. 2020 Dec;27(18):1934-1941
pubmed: 32122201
Acta Neurol Scand. 2011 Apr;123(4):289-93
pubmed: 21361878

Auteurs

Alexander Zabala (A)

Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, 11883, Stockholm, Sweden. alexander.zabala@sll.se.

Vladimer Darsalia (V)

Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, 11883, Stockholm, Sweden.

Marcus Lind (M)

Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, NU Hospital Group, Uddevalla, Sweden.

Ann-Marie Svensson (AM)

Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Centre of Registers in Region Västra Götaland, Gothenburg, Sweden.

Stefan Franzén (S)

Centre of Registers in Region Västra Götaland, Gothenburg, Sweden.

Björn Eliasson (B)

Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

Cesare Patrone (C)

Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, 11883, Stockholm, Sweden.

Magnus Jonsson (M)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden.

Thomas Nyström (T)

Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, 11883, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH